Harbin Jingquan Pharmaceutical Technology

Harbin Jingquan Pharmaceutical Technology was a Chinese pharmaceutical research and development company based in Harbin, Heilongjiang. The company specialized in the development of generic versions of complex small molecule therapeutics, with a focus on psychiatric and inflammatory conditions. Its pipeline included generic versions of Apremilast for psoriasis and Brexpiprazole for schizophrenia and major depressive disorder. Harbin Jingquan operated in close association with Beijing Fukangren Bio-pharmaceutical Technology, a prominent Chinese R&D firm. The company was involved in clinical trial applications and bioequivalence studies for its pipeline candidates before being officially deregistered in November 2023.